Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson’s disease
Objective: The aim of this study is to evaluate the pharmacokinetics of levodopa in patients with Parkinson’s disease (PD) who underwent gastrointestinal surgery. Background: Levodopa…Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients, the ability of opicapone (OPC) to act as levodopa-sparing agent. Background: OPC, a once-daily COMT inhibitor,…Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease
Objective: Our objective was to examine the effects of broad-based tyrosine kinase inhibition in cerebrospinal fluid biomarkers. Background: Nilotinib is a broad-based tyrosine kinase inhibitor…Results of community pharmacist-led structured medication reviews in Parkinson’s Disease
Objective: To obtain insight in the process of community pharmacist-led structured medication reviews in patients with Parkinson’s disease (PD), by evaluating medication modifications and recommendations, and…Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality
Objective: We sought to analyze the mortality and the causes of death of 105 patients with Parkinson disease (PD) treated with levodopa-carbidopa intestinal gel (LCIG)…The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program
Objective: To assess the impact of Gocovri® (amantadine) extended release capsules on motor aspects of experiences of daily living in PD patients. Background: Gocovri is…The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program
Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia
Objective: Introduce the mechanism of action for dopamine D1 positive allosteric modulator (D1PAM) as a new target for neuropsychiatric disorders. Describe the preclinical profile of…Parkinson Kinetigraph – does it change the management of PD patients?
Objective: This pragmatic randomized open trial evaluated if the information from a Parkinson Kinetigraph (PKG) recording changed the management of PD patients at a visit…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 34
- Next Page »